Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
Authors
Keywords
-
Journal
DRUG DELIVERY
Volume 29, Issue 1, Pages 1335-1344
Publisher
Informa UK Limited
Online
2022-05-04
DOI
10.1080/10717544.2022.2069883
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
- (2021) Xoan Nguyen et al. ANNALS OF PHARMACOTHERAPY
- Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
- (2021) Masahiko Aoki et al. Gastric Cancer
- Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
- (2021) Yingying Xu et al. Gastric Cancer
- HER2-targeted therapies in gastric cancer
- (2021) Yinxing Zhu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Disitamab Vedotin: First Approval
- (2021) Emma D. Deeks DRUGS
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- (2021) Zhi Peng et al. Cancer Communications
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
- (2020) Byoungsan Choi et al. eLife
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
- (2020) Michelle D. Hackshaw et al. BREAST CANCER RESEARCH AND TREATMENT
- Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)
- (2020) Sajad Yaghoubi et al. Breast Cancer
- New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
- (2020) Vajihe Akbari et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer
- (2020) Carolyn Cullinane et al. JAMA Network Open
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
- (2019) Lucia D’Amico et al. Journal for ImmunoTherapy of Cancer
- A survival guide to HER 2 testing in gastric/gastroesophageal junction carcinoma
- (2019) Duminda Subasinghe et al. GASTROINTESTINAL ENDOSCOPY
- Targeting PI3K signaling in cancer: Challenges and advances
- (2019) Maria Chiara De Santis et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
- (2019) Noam Pondé et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
- (2019) Kohei Shitara et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- (2019) Reshma Mahtani et al. Clinical Breast Cancer
- ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies
- (2019) Nooshafarin Amani et al. Current Drug Delivery
- Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine
- (2019) Natansh D. Modi et al. Clinical Breast Cancer
- Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
- (2019) Padmanee Sharma et al. CLINICAL CANCER RESEARCH
- HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter
- (2019) Takashi Yorozu et al. Clinical Genitourinary Cancer
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer
- (2018) Meghdad Abdollahpour-Alitappeh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria
- (2016) Katerina Rohlenova et al. BIOLOGICAL CHEMISTRY
- An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
- (2016) Hongwen Li et al. CANCER BIOLOGY & THERAPY
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- HER2-targeted antibody drug conjugates for ovarian cancer therapy
- (2016) Jing Jiang et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery
- (2015) L. Buckel et al. CANCER RESEARCH
- Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes
- (2015) Paul R Moody et al. MOLECULAR THERAPY
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
- (2014) J. P. B. O'Connor et al. CLINICAL CANCER RESEARCH
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
- (2011) Achim Fleischmann et al. EUROPEAN UROLOGY
- Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma
- (2011) Antarpreet Kaur et al. EXPERT OPINION ON PHARMACOTHERAPY
- Quality assessment of HER2 testing by monitoring of positivity rates
- (2011) Harald Choritz et al. VIRCHOWS ARCHIV
- Low frequency of HER2 amplification and overexpression in early onset gastric cancer
- (2011) Cathy B. Moelans et al. CELLULAR ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search